News
Geneva, Switzerland, July 1, 2021 – AMAL Therapeutics announced today that the latest findings of its in vivo research team is on line on the Frontiers in Immunology website.
Geneva, Switzerland, February 17, 2021 – AMAL Therapeutics announced today that its recent research findings, in collaboration with Fox Chase Cancer Center, about a novel protein‐based vaccine against self‐antigen reducing the formation of sporadic colon adenomas in mice, is on line on the Cancers website.
A very happy holiday season from the whole AMAL team, and a great start into 2021!
We are very happy to welcome Thomas Bogenrieder, MD, PhD, as Chief Clinical Officer of AMAL Therapeutics as of July 1, 2020. Thomas will join AMAL’s operations in Geneva.
Boehringer Ingelheim today announced its acquisition of all shares of AMAL Therapeutics SA, a private Swiss biotechnology company focused on cancer immunotherapy and advancing first-in-class therapeutic cancer vaccines derived from its technology platform KISIMA.